Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01. The market awaits NeoGenomics's ...

Delcath Systems’ strong Q1 2025 performance underscores its momentum in expanding HEPZATO’s adoption across the U.S. and advancing its clinical trial pipeline. With a positive cash flow, no debt, and ...

Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) will be featured at the 2025 ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

Analysts have recently evaluated Veracyte and provided 12-month price targets. The average target is $44.71, accompanied by a ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Edna Bonhomme, author of "A History of the World in Six Plagues," details how pandemics are about more than viruses ...

Learn more about whether Option Care Health, Inc. or Premier, Inc. is a better investment based on AAII's A+ Investor grades, ...

Advances in AI, genomics, and liquid biopsy are reshaping cancer care, but systemic gaps persist in access and funding, ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

After further evaluation, she was diagnosed with cholangiocarcinoma, or bile duct cancer, a rare and aggressive cancer that ...